What AEROGEN PHARMA does

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing inhaled drug/device combination products for acute and critical care, with a primary focus on AeroFact (APC-0101), an investigational non-invasive pulmonary surfactant therapy for respiratory distress syndrome (RDS) in preterm infants. Its lead program combines Lyomark's Alveofact bovine lung surfactant with the company's proprietary Photo-Defined Aperture Plate (PDAP) vibrating mesh nebulizer, which generates 1–3 μm aerosol droplets synchronized with infant inspiration to enable trans-nasal delivery via nCPAP or non-invasive ventilation without intubation. The PDAP platform is the only system demonstrated to aerosolize high-viscosity, low-surface-tension surfactant formulations, addressing a 60+ year industry failure point.

The company is the drug development arm of the Aerogen Group — the global market leader in hospital aerosol drug delivery with an installed base reaching 16M+ patients across 75 countries — giving it privileged access to a compatible hospital nebulizer hardware footprint and clinical relationships in neonatal intensive care units. Aerogen Pharma is headquartered in Galway, Ireland, with US development operations in San Mateo, California and Morrisville, North Carolina. AeroFact has secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, plus parallel EMA Fast Track and Orphan Drug designations, and is currently in a Phase 2b trial across approximately 42 US and Canadian sites with a pivotal Phase 3 study anticipated in 2025.

The business model is multi-layered: future commercial product sales (post-approval) of combination drug/device products, upfront and milestone-based licensing revenue (exemplified by the 2021 Nuance Pharma Greater China deal worth up to $212.5M+), development services for pharma partners seeking to use the PDAP platform, and grant-funded global health development supported by the Bill & Melinda Gates Foundation for low- and middle-income country deployment. Primary customer segments are hospital NICUs (Level II–IV) for AeroFact adoption and pharmaceutical/biotech partners for PDAP-enabled development programs.

Name

AEROGEN PHARMA

Legal name

Aerogen Pharma Limited

Website

https://aerogenpharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing the AeroFact inhaled surfactant and proprietary PDAP vibrating mesh nebulizer platform for non-invasive treatment of respiratory distress syndrome in preterm infants, targeting hospital neonatal ICUs and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Inhaled Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ), Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management (HLAKANAM)

Keywords

• Inhaled drug delivery
• Neonatal respiratory therapeutics
• Pulmonary surfactant therapy
• Aerosolized pharmaceutical products
• Drug-device combination products

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Product Sales (Post-Approval): Revenue from sales of proprietary inhaled drug/device combination products, primarily AeroFact for neonatal RDS treatment, upon regulatory approval.
2. Licensing and Milestone Payments: Upfront payments, equity stakes, and development/regulatory/commercial milestone payments from partners such as Nuance Pharma ($20M upfront + $10M equity + up to $182.5M milestones + tiered royalties for Greater China rights).
3. Partnership Development Services: Revenue from consulting and advisory services in aerosol delivery, respiratory care, and regulatory/CMC/clinical aspects of inhaled drug development offered to development partners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Aerogen Pharma develops proprietary inhaled drug/device combination products for acute and critical care, with its lead program AeroFact (APC-0101) delivering non-invasive pulmonary surfactant via the patented PDAP vibrating mesh nebulizer to treat respiratory distress syndrome in preterm infants. The company pairs high-performance aerosol delivery technology with proven therapeutic molecules for hospital-based critical care and offers its PDAP platform for partner-driven development of inhaled NCEs, NBEs, and generics.

Product overview

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing inhaled drug/biologic and device combination products for acute and critical care patients. The company's portfolio centers on AeroFact™ (APC-0101), an investigational non-invasive surfactant replacement therapy for respiratory distress syndrome in preterm infants, which combines a bovine lung surfactant with the proprietary PDAP (Photo-Defined Aperture Plate) vibrating mesh delivery technology. The PDAP platform enables ultra-respirable aerosol generation synchronized with patient inspiration for targeted lung delivery.

Differentiator

Problem solved

Functional benefit

Brands

• AeroFact: Phase 3 development program for investigational non-invasive pulmonary surfactant treatment for respiratory distress syndrome in preterm infants.
• PDAP (Photo-Defined Aperture Plate)

Products and services

• AeroFact (APC-0101) Investigational biologic/device combination product for non-invasive surfactant replacement therapy to treat respiratory distress syndrome (RDS) in preterm infants. Delivered via nasal CPAP or non-invasive ventilation using a vibrating mesh nebulizer synchronized with infant inspiration. The product combines a bovine lung surfactant (Alveofact) with the proprietary PDAP delivery technology to enable aerosolized surfactant administration without intubation.

Quantifiable outcome

• Ultra-respirable 1-3 μm aerosol droplet size for optimal alveolar deposition
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Nuance PharmacoreStrategic or Co-development Partner · 22 December 2021Exclusive licensing agreement granting Nuance Pharma rights to develop and commercialize AeroFact for RDS treatment in Greater China (Mainland China, Taiwan, Hong Kong, Macau). Aerogen receives $20M upfront, $10M equity in Nuance, potential milestones of $182.5M, plus escalating tiered low double-digit royalties on net sales.
• Lyomark PharmacoreStrategic or Co-development Partner · 7 December 2017Development partnership to create AP-002 inhaled surfactant combining Lyomark's Alveofact (bovine lung surfactant) with Aerogen's PDAP delivery technology. Partners collaborating to commercialize and distribute AP-002 globally. Phase 2 clinical trial initiated in Australia.
• Aerogen Limited (Sister Company)coreTechnology or IntegrationAerogen Pharma is the drug development arm of Aerogen Group. Aerogen Limited is the global market leader in high performance aerosol drug delivery, providing commercial nebulizer technology and distribution infrastructure (16M+ patients in 75 countries).
• The Bill & Melinda Gates FoundationflagshipStrategic or Co-development PartnerGates Foundation funding to develop Efficient, Safe, Feasible and Cost-Effective surfactant treatment for preterm infants in low- and middle-income countries. Shared goal of reducing infant mortality in resource-limited settings where RDS fatality rates range from 57-89%.

Scale indicators2 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• Chiesi Farmaceutici: Chiesi is a leading manufacturer of pulmonary surfactants (Curosurf) used to treat neonatal RDS — the most direct incumbent competitor Aerogen Pharma will face upon AeroFact approval in NICU formularies worldwide.
• AbbVie / Abbott (Survanta): AbbVie's Survanta (beractant) is a widely used bovine-derived surfactant for neonatal RDS and a direct competitor to AeroFact's non-invasive delivery of bovine surfactant. Both target the same NICU patient population.
• ONY Biotech (Infasurf): ONY Biotech markets Infasurf (calfactant), another surfactant approved for neonatal RDS. It is a direct therapeutic competitor whose established relationships with U.S. NICUs AeroFact must overcome.

Emerging players

• Verona Pharma: Verona Pharma develops inhaled respiratory therapeutics (ensifentrine/Ohtuvayre) and shares the drug-device combination product profile in respiratory medicine, with similar late-stage clinical and regulatory execution risk.
• INHALON Biopharma: INHALON Biopharma is an early-stage company developing inhaled therapeutics for respiratory infections using an ion-channel-enabled delivery platform, broadly comparable as a specialty inhaled therapeutics peer targeting critical-care and pulmonary indications.
• Savara Inc. Savara is a clinical-stage rare respiratory disease company developing inhaled therapies (e.g., molgramostim for aPAP), offering a comparable specialty pharma profile, late-stage clinical execution model, and orphan-drug pathway experience.

Others

• Aerogen Limited: Aerogen Limited is the sister company and global market leader in hospital vibrating-mesh nebulizers. It supplies the underlying aerosol platform technology that Aerogen Pharma extends with PDAP, making it both a critical technology partner and a closely comparable device peer.

Broad incumbents

• Vyaire Medical: Vyaire Medical is a global respiratory and ventilation equipment incumbent whose neonatal ventilator and aerosol delivery products overlap with the NICU channel Aerogen Pharma will use for AeroFact distribution.

Regional players

• Lyomark Pharma: Lyomark Pharma is the German-based supplier of Alveofact (the bovine surfactant API in AeroFact) and a development partner. While not a direct competitor, it is comparable as a regional specialty respiratory pharma focused on surfactant delivery.
• Nuance Pharma: Nuance Pharma is the Greater China licensee for AeroFact and a regional specialty pharma player focused on critical care and rare disease, making it a comparable regional commercialization model for AeroFact in Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aerogen-pharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AEROGEN PHARMA